Diagnosis and interventions for central serous chorioretinopathy: Review and update

Clinical and Experimental Ophthalmology

Volumn 41, Issue 2, 2013, Pages 187-200

  Quin, Godfrey ^a,c   Liew, Gerald ^a,b   Ho, I Van ^a,c   Gillies, Mark ^a   Fraser Bell, Samantha ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

Central serous chorioretinopathy; Indocyanine green angiography; Laser photocoagulation; Retina

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; INDOCYANINE GREEN; KETOCONAZOLE; METIPRANOLOL; METOPROLOL; MIFEPRISTONE; PROPRANOLOL; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VERTEPORFIN;

CENTRAL SEROUS RETINOPATHY; CHOROID DISEASE; DIFFERENTIAL DIAGNOSIS; DIODE LASER; DISEASE COURSE; DISEASE SEVERITY; DRUG INHIBITION; FLUORESCENCE ANGIOGRAPHY; FOCAL LASER PHOTOCOAGULATION; FUNDUS AUTOFLUORESCENCE; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; LASER; LASER COAGULATION; LOW LEVEL LASER THERAPY; MICROPERIMETRY; MICROPULSE DIODE LASER; MULTIFOCAL ELECTRORETINOGRAPHY; NEAR INFRARED AUTOFLUORESCENCE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT MONITORING; PERIMETRY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SUBRETINAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY; TREATMENT OUTCOME; VISUAL DISORDER;

CENTRAL SEROUS CHORIORETINOPATHY; COLORING AGENTS; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; LASER COAGULATION; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84875504590     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2012.02847.x     Document Type: Review

References (108)

1. Montero JA, Ruiz-Moreno JM. Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy. Br J Ophthalmol 2005; 89: 562-4.
2. Spitznas M. Central serous chorioretinopathy. In: Ryan SJ, ed. Retina. St Louis, MO: Mosby, 1989; 217-27.
3. Mitarai K, Gomi F, Tano Y. Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1415-20.
4. Wang G-H, Zhang J, Zhang D, Lv F-L, Wang L-X. Value of three-dimensional optical coherence tomography and fundus photochromy in correlating the fluorescein leaking sites of acute central serous chorioretinopathy. Med Princ Pract 2011; 20: 283-6.
5. Fujimoto H, Gomi F, Wakabayashi T, Sawa M, Tsujikawa M, Tano Y. Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography. Ophthalmology 2008; 115: 1494-500.
6. Hussain N, Baskar A, Ram LM, Das T. Optical coherence tomographic pattern of fluorescein angiographic leakage site in acute central serous chorioretinopathy. Clin Experiment Ophthalmol 2006; 34: 137-40.
7. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2011; 29: 1469-73.
8. Kim YT, Kang SW, Bai KH. Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye 2011; 25: 1635-40.
9. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010; 117: 1792-9.
10. Pryds A, Larsen M. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Acta Ophthalmol (Copenh) 2011; 17: 211-16.
11. Spitznas M, Huke J. Number, shape, and topography of leakage points in acute type I central serous retinopathy. Graefes Arch Clin Exp Ophthalmol 1987; 225: 437-40.
12. Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986; 224: 321-4.
13. Ie D, Yannuzzi LA, Spaide RF, Rabb MF, Blair NP, Daily MJ. Subretinal exudative deposits in central serous chorioretinopathy. Br J Ophthalmol 1993; 77: 349-53.
14. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984; 68: 815-20.
15. Yamada K, Hayasaka S, Setogawa T. Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit. Ophthalmologica 1992; 205: 69-76.
16. Tobari I, Shimizu K. [Fluorography and photocoagulation of central serous retinopathy]. Nihon Ganka Gakkai Zasshi 1971; 75: 596-602.
17. Guyer DRGE. Central serous chorioretinopathy. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Vol. 2. Philadelphia, PA: WB Suanders, 1994; 1818-25.
18. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol 2012; [Epub ahead of print] doi: 10.1111/j.1442-9071.2012.02848.x.
19. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994; 112: 1057-62.
20. Menchini U, Virgili G, Lanzetta P, Ferrari E. Indocyanine green angiography in central serous chorioretinopathy. ICG angiography in CSC. Int Ophthalmol 1997; 21: 57-69.
21. Ho I, Yannuzzi LA. Chronic central serous and fundus autofluorescence. Ret Cases Brief Reports 2008; 2: 1-5.
22. Spaide RF, Hall L, Haas A etal. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996; 16: 203-13.
23. Avvad FK, Duker JS, Reichel E, Margolis TI, Puliafito CA. The digital indocyanine green videoangiography characteristics of well-defined choroidal neovascularization. Ophthalmology 1995; 102: 401-5.
24. Eandi CM, Ober M, Iranmanesh R, Peiretti E, Yannuzzi LA. Acute central serous chorioretinopathy and fundus autofluorescence. Retina 2005; 25: 989-93.
25. Dinc UA, Tatlipinar S, Yenerel M, Görgün E, Ciftci F. Fundus autofluorescence in acute and chronic central serous chorioretinopathy. Clin Exp Optom 2011; 94: 452-7.
26. Framme C, Walter A, Gabler B, Roider J, Sachs HG, Gabel V. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand 2005; 83: 161-7.
27. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995; 36: 718-29.
28. Ayata A, Tatlipinar S, Kar T, Unal M, Ersanli D, Bilge AH. Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 2009; 93: 79-82.
29. Sekiryu T, Iida T, Maruko I, Saito K, Kondo T. Infrared fundus autofluorescence and central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2010; 51: 4956-62.
30. Marmor MF, Tan F. Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities. Arch Ophthalmol 1999; 117: 184-8.
31. Chappelow AV, Marmor MF. Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy. Arch Ophthalmol 2000; 118: 1211-15.
32. Suzuki K, Hasegawa S, Usui T etal. Multifocal electroretinogram in patients with central serous chorioretinopathy. Jpn J Ophthalmol 2001; 46: 308-14.
33. Dohrmann J, Lommatzsch A, Spital G, Pauleikhoff D. [Pathogenesis of central serous chorioretinopathy: angiographic and electrophysiological studies]. Ophthalmologe 2001; 98: 1069-73.
34. Ehrlich R, Mawer NP, Mody CH, Brand CS, Squirrell D. Visual function following photodynamic therapy for central serous chorioretinopathy: a comparison of automated macular microperimetry versus best-corrected visual acuity. Clin Experiment Ophthalmol 2012; 40: e32-9.
35. Kim SW, Oh J, Huh K. Correlations among various functional and morphological tests in resolved central serous chorioretinopathy. Br J Ophthalmol 2012; 96: 350-5.
36. Ojima Y, Tsujikawa A, Hangai M etal. Retinal sensitivity measured with the micro perimeter 1 after resolution of central serous chorioretinopathy. Am J Ophthalmol 2008; 146: 77-84.
37. Minckler D. Evidence-based ophthalmology series and content-based continuing medical education for the journal. Ophthalmology 2000; 107: 9-10.
38. Sharma T, Shah N, Rao M etal. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 2004; 111: 1708-14.
39. Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry 1987; 144: 46-50.
40. Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K. Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992; 2: 103-14.
41. Gass JD. Photocoagulation treatment of idiopathic central serous choroidopathy. Transactions. Section on Ophthalmology. Am Acad Ophthalmol Otolaryngol 1977; 83(Pt 1): 456-67.
42. Spalter HF. Photocoagulation of central serous retinopathy. A preliminary report. Arch Ophthalmol 1968; 79: 247-53.
43. Kanagawa M, Matsubara M. [Xenon light-exposure as a treatment of central serous retinopathy]. Nihon Ganka Kiyo 1970; 21: 451-3.
44. Landers MB, Shaw HE, Anderson WB, Sinyai AJ. Argon laser treatment of central serous chorioretinopathy. Ann Ophthalmol 1977; 9: 1567-72.
45. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983; 95: 457-66.
46. Annesley WH, Augsburger JJ, Shakin JL. Ten year follow-up of photocoagulated central serous choroidopathy. Trans Am Ophthalmol Soc 1981; 79: 335-46.
47. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol 1996; 114: 689-92.
48. Brancato R, Scialdone A, Pece A, Coscas G, Binaghi M. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch Clin Exp Ophthalmol 1987; 225: 166-8.
49. Castro-Correia J, Coutinho MF, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol 1992; 81: 379-86.
50. Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988; 72: 829-34.
51. Robertson DM. Argon laser photocoagulation treatment in central serous chorioretinopathy. Ophthalmology 1986; 93: 972-4.
52. Slusher MM. Krypton red laser photocoagulation in selected cases of central serous chorioretinopathy. Retina 1986; 6: 81-4.
53. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984; 91: 1554-72.
54. Piccolino FC. Laser treatment of eccentric leaks in central serous chorioretinopathy resulting in disappearance of untreated juxtafoveal leaks. Retina 1992; 12: 96-102.
55. Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979; 63: 674-7.
56. Yannuzzi LA, Slakter JS, Gross NE etal. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288-98.
57. Cardillo Piccolino F, Eandi CM, Ventre L. Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752-63.
58. Chan W-M, Lam DSC, Lai TYY, Tam BSM, Liu DTL, Chan CKM. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87: 1453-8.
59. Canakis C, Livir-Rallatos C, Panayiotis Z etal. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 2003; 136: 750-2.
60. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004; 137: 1073-80.
61. Schlötzer-Schrehardt U, Viestenz A, Naumann GOH, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002; 240: 748-57.
62. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002; 43: 830-41.
63. Yaman A, Arikan G, Saatci AO, Cingil G. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol 2007; 303: 69-73.
64. Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009; 53: 52-6.
65. Leng T, Sanislo SR, Jack RL. Photodynamic therapy rescue for subretinal fluid exacerbation after focal laser treatment in idiopathic central serous chorioretinopathy. Open Ophthalmol J 2011; 5: 6-9.
66. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010; 149: 361-3.
67. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 2010; 149: 441-6.
68. Blumenkranz MS, Bressler NM, Bressler SB etal. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report no. 5. Arch Ophthalmol 2002; 120: 1307-14.
69. Blinder KJ, Blumenkranz MS, Bressler NM etal. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003; 110: 667-73.
70. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008; 115: 1756-65.
71. Lai TYY, Chan W-M, Li H, Lai RYK, Liu DTL, Lam DSC. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006; 90: 869-74.
72. Wu ZHY, Lai RYK, Yip YWY, Chan WM, Lam DSC, Lai TYY. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 2011; 31: 1378-86.
73. Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 2011; 151: 303-9.
74. Rouvas A, Stavrakas P, Theodossiadis PG etal. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol 2012; 22: 417-22.
75. Lim JW, Kang SW, Kim Y-T, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol 2011; 95: 514-17.
76. Reibaldi M, Cardascia N, Longo A etal. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010; 149: 307-15.
77. Shin JY, Woo SJ, Yu HG, Park KH. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011; 31: 119-26.
78. Zhao M-W, Zhou P, Xiao H-X etal. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina 2009; 29: 1155-61.
79. Brancato R, Pratesi R, Leoni G, Trabucchi G, Vanni U. Histopathology of diode and argon laser lesions in rabbit retina. A comparative study. Invest Ophthalmol Vis Sci 1989; 30: 1504-10.
80. Verma L, Sinha R, Venkatesh P, Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial. BMC Ophthalmol 2004; 4: 15.
81. Ricci F, Missiroli F, Cerulli L. Indocyanine green dye-enhanced micropulsed diode laser: a novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy. Eur J Ophthalmol 2004; 14: 74-82.
82. Chen S-N, Hwang J-F, Tseng L-F, Lin C-J. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 2008; 115: 2229-34.
83. Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol 2008; 18: 934-40.
84. Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye 2008; 22: 100-6.
85. Wei S-Y, Yang C-M. Transpupillary thermotherapy in the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2005; 36: 412-15.
86. Sharma T, Parikh SD. Transpupillary thermotherapy for juxtafoveal leak in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2010; 9: 1-3.
87. Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2011; 249: 969-74.
88. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol 2010; 24: 155-8.
89. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010; 35: 91-8.
90. Chhablani JK, Narayanan R. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010; 30: 1323-4.
91. Inoue M, Kadonosono K, Watanabe Y, Kobayashi S, Yamane S, Arakawa A. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. Ophthalmologica 2011; 225: 37-40.
92. Lee ST, Adelman RA. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab. J Ocul Pharmacol 2011; 27: 611-14.
93. Alomran MS. Intravitreal bevacizumab for the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2010; 2: 1-3.
94. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010; 30: 100-6.
95. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2010; 19: 613-17.
96. Huang W-C, Chen W-L, Tsai Y-Y, Chiang C-C, Lin J-M. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye 2009; 23: 488-9.
97. Torres-Soriano ME, García-Aguirre G, Kon-Jara V etal. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008; 246: 1235-9.
98. Lee JY, Chae JB, Yang SJ, Kim J-G, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol (Copenh) 2011; 89:e293-4.
99. Ibrahim MA, Sepah YJ, Symons RCA etal. Spectral- and time-domain optical coherence tomography measurements of macular thickness in normal eyes and in eyes with diabetic macular edema. Eye 2011; 2: 293-4.
100. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis 1999; 5: 34-9.
101. Lim JW, Kim MU, Shin M-C. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010; 30: 1465-71.
102. Arevalo JF, Espinoza JV. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2011; 249: 1159-66.
103. Nielsen JS, Weinreb RN, Yannuzzi L, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina 2007; 27: 119-22.
104. Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina 2011; 31: 1928-36.
105. Golshahi A, Klingmüller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol (Copenh) 2010; 88: 576-81.
106. Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther 2006; 22: 145-9.
107. Chrapek O, Spacková K, Rehák J. [Treatment of central serous chorioretinopathy with beta blockers]. Ceská A Slovenská Oftalmologie 2002; 58: 382-6.
108. Fabianová J, Porubská M, Cepilová Z. [Central serous chorioretinopathy - treatment with beta blockers]. Ceská A Slovenská Oftalmologie 1998; 54: 401-4.